scholarly journals Long-term survivors of childhood bone and soft tissue sarcomas are at risk of hospitalization

2016 ◽  
Vol 64 (6) ◽  
pp. e26371 ◽  
Author(s):  
Cristian D. Gonzalez ◽  
R. Lor Randall ◽  
Jennifer Wright ◽  
Holly Spraker-Perlman ◽  
Jian Ying ◽  
...  
Keyword(s):  
At Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Long Term Survivors

Hematopoietic Stem Cell Transplantation and Secondary Primary Malignancies in Taiwan

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4219-4219 ◽  
Author(s):  
Chia-Jen Liu ◽  
Kuo-Wei Chen ◽  
Yu-Wen Hu ◽  
Ying-Chung Hong ◽  
Yu-Chung Huang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Soft Tissue ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hematological Malignancies ◽  
Soft Tissue Sarcomas ◽  
Cancer Development ◽  
Hematopoietic Stem ◽  
Long Term Survivors

Abstract Abstract 4219 Objectives Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many hematological disorders. The improvement of HSCT may lead to longer overall survival of patients with catastrophic illness and the risk of secondary cancer development become an emerging issue in long-term survivors. Patients and Methods We conducted a nationwide population-based study of 1,881 patients with hematologic diseases undergoing HSCT between January, 1997 and January, 2007 using Taiwan's National Health Insurance Research database. Performing HSCT to treat non-hematological diseases were excluded. All patients were followed until solid cancer development, death, or the end of 2010. We did not put hematological malignancies as endpoint because solid tumors and hematological malignancies might have different carcinogensis mechanism. We used standardized incidence ratios (SIRs) to compare patterns of cancer incidence in patients with those of the general population. Multivariate analysis was undertaken using Cox proportional-hazards regression using a forward selection, likelihood ratio model to identify independent predictors of cancer development among patients after HSCT. Results We observed a total of 8,753.87 person-years in this study. Patients received HSCT had a significant increased risk of developing any kind of cancer (SIR 1.77, 95% confidence interval [CI] 1.15 – 2.62; p = 0.011). Specifically, patients after HSCT had increased cancer incidence of head and neck cancer (SIR 3.96, 95% CI 1.90 – 7.29; p < 0.001) and bone and soft tissue sarcomas (SIR 10.08, 95% CI 1.22 – 36.42; p = 0.035). In subgroup analyses, cancers were more likely to develop in patients aged 0 – 19 years (SIR 22.31, 95% CI 4.60 – 65.20; p < 0.001), and those who survived more than 5 years after HSCT (SIR 3.30, 95% CI 1.96 – 5.22; p < 0.001). Conclusion Our study demonstrates an increased incidence of cancer development in patients after HSCT, especially malignancies of head and neck and also bone and soft tissue sarcomas. Patients aged 0 – 19 years and those survived more than 5 years after HSCT have a higher incidence of developing cancer comparing to normal population. HSCT long-term survivors should therefore be monitored more carefully for cancer development and targeted with preventive intervention strategies. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Variation of Second Cancer Risk by Family History of Retinoblastoma Among Long-Term Survivors

2012 ◽  
Vol 30 (9) ◽  
pp. 950-957 ◽  
Author(s):  
Ruth A. Kleinerman ◽  
Chu-ling Yu ◽  
Mark P. Little ◽  
Yi Li ◽  
David Abramson ◽  
...  
Keyword(s):  
Family History ◽  
Soft Tissue ◽  
Germline Mutation ◽  
De Novo ◽  
Soft Tissue Sarcomas ◽  
Second Cancer ◽  
History Of ◽  
Long Term Survivors

Purpose To evaluate the risk of second cancer (SC) in long-term survivors of retinoblastoma (Rb) according to classification of germline mutation, based on family history of Rb and laterality. Patients and Methods We assembled a cohort of 1,852 1-year survivors of Rb (bilateral, n = 1,036; unilateral, n = 816). SCs were ascertained by medical records and self-reports and confirmed by pathology reports. Classification of RB1 germline mutation, inherited or de novo, was inferred by laterality of Rb and positive family history of Rb. Standardized incidence ratios and cumulative incidence for all SCs combined and for soft tissue sarcomas, bone cancers, and melanoma were calculated. The influence of host- and therapy-related risk factors for SC was assessed by Poisson regression for bilateral survivors. Results We observed a relative risk (RR) of 1.37 (95% CI, 1.00 to 1.86) for SCs in bilateral survivors associated with a family history of Rb, adjusted for treatment, age, and length of follow-up. The risk for melanoma was significantly elevated for survivors with a family history of Rb (RR, 3.08; 95% CI, 1.23 to 7.16), but risks for bone or soft tissue sarcomas were not elevated. The cumulative incidence of SCs 50 years after diagnosis of bilateral Rb, with adjustment for competing risk of death, was significantly higher for survivors with a family history (47%; 95% CI, 35% to 59%) than survivors without a family history (38%; 95% CI, 32% to 44%; P = .004). Conclusion Rb survivors with bilateral disease and an inherited germline mutation are at slightly higher risk of an SC compared with those with a de novo germline mutation, in particular melanoma, perhaps because of shared genetic alterations.

scholarly journals A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1046
Author(s):  
Chait-Rubinek ◽  
Mariani ◽  
Goroncy ◽  
Herschtal ◽  
Wheeler ◽  
...  
Keyword(s):  
At Risk ◽  
Young Adult ◽  
Cancer Diagnosis ◽  
Cardiac Dysfunction ◽  
Adolescent And Young Adult ◽  
Cardiac Events ◽  
Increased Risk ◽  
Cardiac Assessment ◽  
Long Term Survivors

Long-term survivors of childhood, adolescent and young adult (AYA) malignancies with past exposure to potentially cardiotoxic treatments are at risk of peripartum cardiac dysfunction. Incidence and risk factors for peripartum cardiac dysfunction and maternal cardiac outcomes in this population were investigated. Eligible long-term survivors were aged <30 years at cancer diagnosis, with ≥1 pregnancy occurring ≥5 years after diagnosis. “Peripartum” cardiac events were defined as occurring within pregnancy or ≤5months after delivery. Cardiac events were classified “symptomatic” or “subclinical”. “Peripartum cardiomyopathy” (PPCM) was defined as symptomatic dysfunction without prior cardiac dysfunction. Of 64 eligible women, 5 (7.8%) had peripartum cardiac events: 3 symptomatic, 2 subclinical. Of 110 live births, 2 (1.8%, 95% CI 0.2–6.4) were defined as PPCM: Significantly greater than the published general population incidence of 1:3000 (p < 0.001), representing a 55-fold (95% CI 6.6–192.0) increased risk. Risk factor analyses were hypothesis-generating, revealing younger age at cancer diagnosis and higher anthracycline dose. Postpartum, cardiac function of 4 women (80%) failed to return to baseline. In conclusion, peripartum cardiac dysfunction is an uncommon but potentially serious complication in long-term survivors of paediatric and AYA malignancies previously treated with cardiotoxic therapies. Peripartum cardiac assessment is strongly recommended for at-risk patients.

Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas

2009 ◽  
Vol 20 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Tal Grenader ◽  
Anthony Goldberg ◽  
Irit Hadas-Halperin ◽  
Alberto Gabizon
Keyword(s):  
Soft Tissue ◽  
Liposomal Doxorubicin ◽  
Soft Tissue Sarcomas ◽  
Pegylated Liposomal Doxorubicin ◽  
Term Response

Extended ray resection for sarcoma of the hand: long-term survival and functional results

2019 ◽  
Vol 45 (2) ◽  
pp. 160-166 ◽  
Author(s):  
Farhad Farzaliyev ◽  
Hans-Ulrich Steinau ◽  
Halil-Ibrahim Karadag ◽  
Alexander Touma ◽  
Lars Erik Podleska
Keyword(s):  
Soft Tissue ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Functional Results ◽  
Contralateral Side ◽  
Level Of Evidence ◽  
Term Survival ◽  
Kaplan Meier

In this retrospective study, we analysed the long-term oncological and functional results after extended ray resection for sarcoma of the hand. Recurrence-free and overall survivals were calculated using the Kaplan–Meier method. The function of the operated hand was assessed with the Michigan Hand Questionnaire and compared with the contralateral side. Extended ray resection was performed in 25 out of 168 consecutive patients with soft-tissue and bony sarcomas of the hand. The overall 5- and 10-year, disease-specific survival rates were 86% and 81%, respectively. Local recurrences were observed in two patients. The Michigan Hand Questionnaire score for the affected hand at follow-up in nine patients was 82 points versus 95 for the healthy contralateral hands. We conclude that extended ray resection of osseous sarcomas breaking through the bone into the soft tissue or for soft tissue sarcomas invading bone is a preferable alternative to hand ablation when excision can be achieved with tumour-free margins. Level of evidence: III

scholarly journals Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity

2020 ◽  
Vol 13 (1) ◽  
pp. 113-119 ◽  
Author(s):  
Magda Cordeiro ◽  
José Manuel Casanova ◽  
Joana Rodrigues ◽  
João Freitas ◽  
Ruben Fonseca ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Soft Tissue ◽  
Lower Extremity ◽  
Disease Progression ◽  
Stable Disease ◽  
Case Reports ◽  
Soft Tissue Sarcomas ◽  
Term Therapy

Leiomyosarcomas of the lower extremity are extremely rare disorders and account for 10–15% of limb soft tissue sarcomas. These tumours have poor prognosis and even in early stages, patients persist at high risk for local and distant relapse; consequently, the treatment of advanced leiomyosarcoma of the lower extremity embodies a substantial defy. We present the case of a 73-year-old man diagnosed with metastatic lower extremity leiomyosarcoma of the hallux soft tissue, and with bone, lung and lymph node metastasis. After core needle biopsy confirmation of high-grade fusocellular sarcoma, the patient underwent surgery of the primary tumour and received anthracycline-based chemotherapy. However, after a 7-month progression-free survival period, a CT revealed lung disease progression. Sequentially, the patient was treated with trabectedin (Yondelis®) at a dose of 1.5 mg/m2 resulting in complete remission of the lung metastasis and stable disease of the remaining lesions after 26 months of treatment. Afterwards, the patient started on maintenance therapy with trabectedin, resulting in long-lasting stable disease, as he was able to receive 94 cycles with very acceptable quality of life. Finally, in March 2019, the patient died of community-acquired pneumonia without objective progression disease. This clinical case reports the first patient ever treated with 94 cycles of trabectedin. Our results additionally confirm that trabectedin wields relevant oncostatic benefits with a manageable safety profile and without cumulative toxicities. Trabectedin properties enable a maintenance long-term therapy (until disease progression or unbearable toxicity), with a high impact on survival and with a preserved quality of life.

Re-excision after unplanned excision of soft tissue sarcomas: Long-term results

2020 ◽  
Vol 34 ◽  
pp. 212-217
Author(s):  
Guido Scoccianti ◽  
Matteo Innocenti ◽  
Filippo Frenos ◽  
Francesco Muratori ◽  
Federico Sacchetti ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Long Term Results ◽  
Unplanned Excision
Sign in / Sign up

Export Citation Format

Share Document